• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析脾边缘区淋巴瘤的遗传学特征。

Unraveling the genetics of transformed splenic marginal zone lymphoma.

机构信息

Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

Universitat de Barcelona, Spain.

出版信息

Blood Adv. 2023 Jul 25;7(14):3695-3709. doi: 10.1182/bloodadvances.2022009415.

DOI:10.1182/bloodadvances.2022009415
PMID:36995085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10368783/
Abstract

The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P = .001; P = .042; and P = .007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event.

摘要

与脾边缘区淋巴瘤 (SMZL) 转化相关的遗传机制尚不清楚。我们研究了 41 例最终发生大 B 细胞淋巴瘤转化的 SMZL 患者。肿瘤标本分别仅在诊断时(9 例)、诊断时和转化时(18 例)以及仅在转化时(14 例)获得。样本分为 2 组:(1)诊断时(SMZL,n=27 个样本),(2)转化时(SMZL-T,n=32 个样本)。使用拷贝数阵列和下一代测序定制面板,我们发现 SMZL-T 的主要基因组改变涉及 TNFAIP3、KMT2D、TP53、ARID1A、KLF2、1q 增益和 9p21.3(CDKN2A/B)和 7q31-q32 的缺失。与 SMZL 相比,SMZL-T 的基因组复杂性更高,TNFAIP3 和 TP53 改变、9p21.3(CDKN2A/B)缺失和 6p 增益的发生率更高。SMZL 和 SMZL-T 克隆是由共同的改变前体细胞通过不同的进化途径产生的,几乎所有可评估的病例(92%,13 例中的 12 例)都获得了不同的遗传改变。对 1 例患者的诊断和转化样本进行全基因组测序后,我们观察到 SMZL-T 样本比诊断样本携带更多的基因组异常,在两个样本中均检测到存在 t(14;19)(q32;q13)易位,并检测到由于转化时获得的染色体碎裂而导致的焦点 B2M 缺失。生存分析显示,KLF2 突变、复杂核型和转化时的国际预后指数评分是预测从转化到死亡的生存时间更短的因素(P=0.001;P=0.042;P=0.007;分别)。总之,SMZL-T 的特点是比 SMZL 具有更高的基因组复杂性,以及特征性的基因组改变,这些改变可能代表转化事件中的关键因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/acde43ed7c71/BLOODA_ADV-2022-009415-gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/bb2afddbff20/BLOODA_ADV-2022-009415-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/37fa8c4fd413/BLOODA_ADV-2022-009415-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/aff8303919b5/BLOODA_ADV-2022-009415-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/d304c9af3856/BLOODA_ADV-2022-009415-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/1f72ae40eacf/BLOODA_ADV-2022-009415-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/f5763b1d080e/BLOODA_ADV-2022-009415-gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/acde43ed7c71/BLOODA_ADV-2022-009415-gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/bb2afddbff20/BLOODA_ADV-2022-009415-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/37fa8c4fd413/BLOODA_ADV-2022-009415-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/aff8303919b5/BLOODA_ADV-2022-009415-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/d304c9af3856/BLOODA_ADV-2022-009415-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/1f72ae40eacf/BLOODA_ADV-2022-009415-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/f5763b1d080e/BLOODA_ADV-2022-009415-gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f6f/10368783/acde43ed7c71/BLOODA_ADV-2022-009415-gr6.jpg

相似文献

1
Unraveling the genetics of transformed splenic marginal zone lymphoma.解析脾边缘区淋巴瘤的遗传学特征。
Blood Adv. 2023 Jul 25;7(14):3695-3709. doi: 10.1182/bloodadvances.2022009415.
2
Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.脾脏边缘区淋巴瘤:7q 缺失的特征及其在诊断中的价值。
J Pathol. 2010 Mar;220(4):461-74. doi: 10.1002/path.2665.
3
Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.脾边缘区淋巴瘤进展为大B细胞淋巴瘤:12例病例系列描述
Am J Surg Pathol. 2001 Oct;25(10):1268-76. doi: 10.1097/00000478-200110000-00007.
4
KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.KLF2 突变是脾边缘区淋巴瘤中最常见的体细胞改变,并确定了具有独特基因型的亚群。
Leukemia. 2015 May;29(5):1177-85. doi: 10.1038/leu.2014.330. Epub 2014 Nov 27.
5
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.伴有组织学转化的脾脏边缘区淋巴瘤患者的临床-生物学特征和结局。
Br J Haematol. 2022 Jan;196(1):146-155. doi: 10.1111/bjh.17815. Epub 2021 Sep 14.
6
Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?以红髓为主受累的脾脏小B细胞淋巴瘤:脾脏边缘区淋巴瘤的一种弥漫性变异型?
Histopathology. 2002 Jan;40(1):22-30. doi: 10.1046/j.1365-2559.2002.01314.x.
7
Exome sequencing identifies recurrent alterations and the absence of , and mutations in splenic diffuse red pulp small B-cell lymphoma.外显子组测序鉴定出脾弥漫性红髓小 B 细胞淋巴瘤中反复出现的改变,以及 和 突变的缺失。
Haematologica. 2017 Oct;102(10):1758-1766. doi: 10.3324/haematol.2016.160192. Epub 2017 Jul 27.
8
7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma.7q31 - 32等位基因缺失在脾边缘区淋巴瘤中是常见的发现。
Am J Pathol. 1999 May;154(5):1583-9. doi: 10.1016/S0002-9440(10)65411-9.
9
Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.通过比较基因组杂交和细胞遗传学揭示的B细胞脾边缘区淋巴瘤中的新型基因组失衡
Am J Pathol. 2001 May;158(5):1843-50. doi: 10.1016/S0002-9440(10)64140-5.
10
Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.髓系核分化抗原:在初次骨髓活检中辅助鉴别淋巴浆细胞淋巴瘤和脾边缘区淋巴瘤。
Hum Pathol. 2022 Jun;124:67-75. doi: 10.1016/j.humpath.2022.03.008. Epub 2022 Mar 23.

引用本文的文献

1
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.惰性B细胞恶性肿瘤向侵袭性B细胞恶性肿瘤转变的分子机制
Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907.
2
Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis.边缘区淋巴瘤的基因改变及其预后影响:一项荟萃分析
Ann Hematol. 2025 Mar;104(3):1307-1315. doi: 10.1007/s00277-024-06175-z. Epub 2025 Jan 17.
3
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study.

本文引用的文献

1
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.检测慢性淋巴细胞白血病中 Richter 转化的早期播种。
Nat Med. 2022 Aug;28(8):1662-1671. doi: 10.1038/s41591-022-01927-8. Epub 2022 Aug 11.
2
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
3
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
惰性淋巴瘤转化与原发性弥漫性大 B 细胞淋巴瘤的对比分析:基于人群的队列研究。
Blood Cancer J. 2024 Nov 29;14(1):212. doi: 10.1038/s41408-024-01194-5.
4
Cyclin-D1 rearrangement as a secondary event in the large cell transformation of splenic marginal zone lymphoma with a TP53 deletion.细胞周期蛋白D1重排作为伴有TP53缺失的脾边缘区淋巴瘤大细胞转化中的继发事件。
Virchows Arch. 2024 Oct 21. doi: 10.1007/s00428-024-03946-x.
5
The genomic landscape of transformed splenic diffuse red pulp small B-cell lymphoma.转化性脾弥漫性红髓小B细胞淋巴瘤的基因组图谱。
EJHaem. 2024 Oct 4;5(5):1014-1020. doi: 10.1002/jha2.1018. eCollection 2024 Oct.
6
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.边缘区淋巴瘤的转化:一项前瞻性队列研究和文献荟萃分析的结果。
Blood Adv. 2024 Dec 10;8(23):5939-5948. doi: 10.1182/bloodadvances.2024013188.
7
Splenic marginal zone lymphoma with prolymphocytic transformation and cyclin D1 expression in the absence of CCND1 rearrangement.脾边缘区淋巴瘤伴前淋巴细胞转化和 cyclin D1 表达,但无 CCND1 重排。
Int J Hematol. 2024 Dec;120(6):750-754. doi: 10.1007/s12185-024-03845-6. Epub 2024 Sep 16.
8
The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications.脾边缘区淋巴瘤的基因组和分子图谱、生物学及临床意义
Explor Target Antitumor Ther. 2024;5(4):877-901. doi: 10.37349/etat.2024.00253. Epub 2024 Jul 23.
9
Advances in the treatment of relapsed/refractory marginal zone lymphoma.复发/难治性边缘区淋巴瘤的治疗进展
Front Oncol. 2024 Jan 25;14:1327309. doi: 10.3389/fonc.2024.1327309. eCollection 2024.
10
The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.结内和脾边缘区淋巴瘤的多面性。2022 年 EA4HP/SH 淋巴瘤研讨会报告。
Virchows Arch. 2023 Sep;483(3):317-331. doi: 10.1007/s00428-023-03633-3. Epub 2023 Sep 1.
成熟淋巴细胞肿瘤国际共识分类:临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
4
Marginal zone lymphoma: present status and future perspectives.边缘区淋巴瘤:现状与未来展望。
Haematologica. 2022 Jan 1;107(1):35-43. doi: 10.3324/haematol.2021.278755.
5
Genetic and phenotypic attributes of splenic marginal zone lymphoma.脾脏边缘区淋巴瘤的遗传和表型特征。
Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386.
6
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.伴有组织学转化的脾脏边缘区淋巴瘤患者的临床-生物学特征和结局。
Br J Haematol. 2022 Jan;196(1):146-155. doi: 10.1111/bjh.17815. Epub 2021 Sep 14.
7
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma.拷贝数signature 可预测初诊多发性骨髓瘤中的 chromothripsis 及临床结局。
Nat Commun. 2021 Aug 27;12(1):5172. doi: 10.1038/s41467-021-25469-8.
8
Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia.在一项多中心研究的 2843 例慢性淋巴细胞白血病患者中,平衡和不平衡易位的情况。
Genes Chromosomes Cancer. 2022 Jan;61(1):37-43. doi: 10.1002/gcc.22994. Epub 2021 Sep 4.
9
Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.MYD88 L256P 突变的频率及其与成熟 B 细胞肿瘤临床血液学特征的相关性。
Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):231-239. doi: 10.1016/j.hemonc.2020.10.003. Epub 2020 Nov 13.
10
Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.基于人群的研究中应用游离 DNA 检测弥漫性大 B 细胞淋巴瘤的突变特征和肿瘤负担
Clin Cancer Res. 2021 Jan 15;27(2):513-521. doi: 10.1158/1078-0432.CCR-20-2558. Epub 2020 Oct 29.